Clarivate Plc Form 8-K Summary
Business context and reporting period
Filed October 6, 2026, reporting completion on that date of Clarivate’s previously announced sale of its Life Sciences and Healthcare business to an affiliate of Altaris, LLC. The purchase agreement was dated July 3, 2026.
Transaction consideration and financial information
- At closing, the buyer paid $500 million in cash, subject to customary adjustments for cash, indebtedness, working capital and transaction expenses.
- The buyer’s affiliate issued Clarivate an unsecured senior note with $75 million principal.
- An additional $25 million is payable after specified transition-services and final-payment conditions are met, and no later than January 31, 2028.
- The filing provides no clear value for the final cash adjustments and does not report resulting proceeds net of adjustments, transaction costs, or debt repayment. It contains no revenue, profit, cash flow, margin, liquidity or debt metrics for the sold business or Clarivate.
Changes, outlook and other matters
Henry Levy, Clarivate’s President, Life Sciences & Healthcare, left employment with a Clarivate subsidiary upon closing. Clarivate entered into a separation agreement and release providing payments and benefits under his previously disclosed retention agreement.
Clarivate said it expects to file unaudited pro forma consolidated financial information by October 13, 2026, covering a June 30, 2026 balance sheet and statements of operations for the six months ended June 30, 2026 and years ended December 31, 2025, 2024 and 2023. The filing provides no other guidance or management commentary. The deferred payment, customary closing adjustments and unsecured note are relevant transaction contingencies.
Key facts for investors to verify
- Final cash proceeds after purchase-price adjustments and transaction expenses.
- Terms, repayment provisions and collectibility of the $75 million unsecured senior note.
- Status and timing of the $25 million deferred payment and transition-services obligations.
- Pro forma financial effects of the divestiture when filed.
- Separation payments and benefits provided to Mr. Levy under the retention agreement.